ERBB2 and breast cancer: In addition, lapatinib, a dual tyrosine kinase inhibitor of EGFR and ERBB2, induced autophagic cell death in breast cancer cells overexpressing ERBB240, human hepatoma cells41, and acute myeloblastic leukemia42.